Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00652704 |
Recruitment Status :
Completed
First Posted : April 4, 2008
Last Update Posted : September 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
To Determine Bioequivalence Under Fed Conditions | Drug: Doxycycline monohydrate Drug: Monodox Drug: Doxycycline Monohydrate | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Randomized, Open-Label, 3-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting and Fed Conditions |
Study Start Date : | July 1999 |
Actual Primary Completion Date : | September 1999 |
Actual Study Completion Date : | September 1999 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
|
Drug: Doxycycline monohydrate
Capsules, 100 mg, fed
Other Name: Monodox |
Active Comparator: B
Subjects received the reference product, Monodox (Oclassen) under fed conditions
|
Drug: Monodox
Capsules, 100 mg, fed
Other Name: Doxycycline Monohydrate |
Experimental: C
Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
|
Drug: Doxycycline Monohydrate
Capsules, 100 mg, fasting
Other Name: Monodox |
- Rate and extent of absorption [ Time Frame: 72 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subjects will be males, non-smokers
- Between 18 and 55 years of age
- Subjects weight will be within 15% of their ideal body weight, based on Table of "Desirable Weight of Adults", Metropolitan Life Insurance Company, 1983
- Subjects should read, sign and date an Informed Consent Form prior to any study procedures
- Subjects must complete all screening procedures within 28 days prior to the administration of the study medication
Exclusion Criteria:
- Clinically significant anormalities found during medical screening
- Any clinically significant history of ongoing problems or problems known to interfere with the absorption, distribution, metabolism or excretion of drugs of drugs
- Clinically significant illnesses within 4 weeks of the administration of study medication
- Abnormal laboratory tests judged clinically significant
- ECG or vital sign abnormalities (clinically significant)
- History of allergic reactions to heparin
- Any food allergies, intolerances, restrictions, or special diet which in the opinion of the medical subinvestigator, contraindicates the subject's participation in the study
- History of severe allergies or hay fever
- Active asthma or bronchospasm
- Positive urine drug screen at screening
- Positive testing for hepatitis B, hepatitis C or HIV at screening
- Use of investigational drug or participation in an investigational study, within 30 days prior to administration of the study medication
- Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
- History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day
- Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana, pot) use within 3 months of the screening visit and hard drugs (cocaine, PCP, crack) use within 1 year of the screening visit
- Subjects who have taken prescription medication 14 days preceding administration of study medication or over-the-counter products 7 days preceding administration of study medication, except for topical products without systemic absorption
- Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
- Subjects who have undergone clinically significant surgery within 4 weeks prior to the administration of the study medication
- Any reason which, in the opinion of the medical subinvestigator, would prevent the subject from participating in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652704
Canada, Quebec | |
Anapharm, Inc. | |
Sainte-Foy, Quebec, Canada, G1V 2K8 |
Principal Investigator: | Eric Masson, Pharm.D. | Anapharm |
Responsible Party: | Alfred Elvin/Director of Biopharmaceutics, Par Pharmaceutical, Inc. |
ClinicalTrials.gov Identifier: | NCT00652704 |
Other Study ID Numbers: |
99062 |
First Posted: | April 4, 2008 Key Record Dates |
Last Update Posted: | September 26, 2017 |
Last Verified: | September 2017 |
Bioequivalence Doxycycline Monohydrate Fed |
Disease Pathologic Processes Doxycycline Anti-Bacterial Agents |
Anti-Infective Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents |